Literature DB >> 20012081

A systematic review on the effect of bevacizumab in exudative age-related macular degeneration.

Christine Schmucker, Gerd Antes, Monika Lelgemann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20012081     DOI： 10.1007/s00417-009-1249-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  7 in total

1.  Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.

Authors:  Ratimir Lazic; Nikica Gabric
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-18       Impact factor: 3.117

2.  Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).

Authors:  Lihteh Wu; María A Martínez-Castellanos; Hugo Quiroz-Mercado; J Fernando Arevalo; María H Berrocal; Michel E Farah; Mauricio Maia; José A Roca; Francisco J Rodriguez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

3.  Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.

Authors:  Ziad F Bashshur; Alexandre Schakal; Rola N Hamam; Christelle P El Haibi; Rola F Jaafar; Baha' N Noureddin
Journal:  Arch Ophthalmol       Date:  2007-10

4.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.

Authors:  A E Fung; P J Rosenfeld; E Reichel
Journal:  Br J Ophthalmol       Date:  2006-07-19       Impact factor: 4.638

6.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

Authors:  David M Brown; Mark Michels; Peter K Kaiser; Jeffrey S Heier; Judy P Sy; Tsontcho Ianchulev
Journal:  Ophthalmology       Date:  2009-01       Impact factor: 12.079

7.  [Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration].

Authors:  R Hahn; S Sacu; S Michels; A Varga; G Weigert; W Geitzenauer; P Vécsei-Marlovits; U Schmidt-Erfurth
Journal:  Ophthalmologe       Date:  2007-07       Impact factor: 1.174
  7 in total
  1 in total

1.  Reduced occurrence of programmed cell death and gliosis in the retinas of juvenile rabbits after shortterm treatment with intravitreous bevacizumab.

Authors:  Maria Alice Fusco; André Luís Freire Portes; Silvana Allodi; Haroldo Vieira de Moraes Junior; Mário Luiz Ribeiro Monteiro; Nádia Campos de Oliveira Miguel
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.